BRIEF-Roche’S Divarasib Demonstrated Best-In-Class Efficacy, Advancing The Standard Of Care In Previously Treated KRAS G12C-Mutated Lung Cancer

4

Oct 25 (Reuters) – Roche Holding AG: * ROCHE’S DIVARASIB DEMONSTRATED BEST-IN-CLASS EFFICACY, ADVANCING THE STANDARD OF CARE IN PREVIOUSLY TREATED KRAS G12C-MUTATED LUNG CANCER * ROCHE HOLDING AG –

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)